Literature DB >> 19966416

Structure of the Taz2 domain of p300: insights into ligand binding.

Maria Miller1, Zbigniew Dauter, Scott Cherry, Joseph E Tropea, Alexander Wlodawer.   

Abstract

CBP and its paralog p300 are histone acetyl transferases that regulate gene expression by interacting with multiple transcription factors via specialized domains. The structure of a segment of human p300 protein (residues 1723-1836) corresponding to the extended zinc-binding Taz2 domain has been investigated. The crystal structure was solved by the SAD approach utilizing the anomalous diffraction signal of the bound Zn ions. The structure comprises an atypical helical bundle stabilized by three Zn ions and closely resembles the solution structures determined previously for shorter peptides. Residues 1813-1834 from the current construct form a helical extension of the C-terminal helix and make extensive crystal-contact interactions with the peptide-binding site of Taz2, providing additional insights into the mechanism of the recognition of diverse transactivation domains (TADs) by Taz2. On the basis of these results and molecular modeling, a hypothetical model of the binding of phosphorylated p53 TAD1 to Taz2 has been proposed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19966416      PMCID: PMC2789004          DOI: 10.1107/S0907444909040153

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  23 in total

Review 1.  CBP/p300 in cell growth, transformation, and development.

Authors:  R H Goodman; S Smolik
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

Review 2.  Post-translational modifications and activation of p53 by genotoxic stresses.

Authors:  E Appella; C W Anderson
Journal:  Eur J Biochem       Date:  2001-05

3.  Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions.

Authors:  E Krissinel; K Henrick
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

4.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

Review 5.  CBP, a transcriptional coactivator and acetyltransferase.

Authors:  K J McManus; M J Hendzel
Journal:  Biochem Cell Biol       Date:  2001       Impact factor: 3.626

6.  Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A.

Authors:  Elena Bochkareva; Lilia Kaustov; Ayeda Ayed; Gwan-Su Yi; Ying Lu; Antonio Pineda-Lucena; Jack C C Liao; Andrei L Okorokov; Jo Milner; Cheryl H Arrowsmith; Alexey Bochkarev
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-17       Impact factor: 11.205

7.  Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation.

Authors:  Hanqiao Feng; Lisa M Miller Jenkins; Stewart R Durell; Ryo Hayashi; Sharlyn J Mazur; Scott Cherry; Joseph E Tropea; Maria Miller; Alexander Wlodawer; Ettore Appella; Yawen Bai
Journal:  Structure       Date:  2009-02-13       Impact factor: 5.006

8.  Comparative study of the p53-mdm2 and p53-MDMX interfaces.

Authors:  V Böttger; A Böttger; C Garcia-Echeverria; Y F Ramos; A J van der Eb; A G Jochemsen; D P Lane
Journal:  Oncogene       Date:  1999-01-07       Impact factor: 9.867

9.  Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation.

Authors:  Lisa M Miller Jenkins; Hiroshi Yamaguchi; Ryo Hayashi; Scott Cherry; Joseph E Tropea; Maria Miller; Alexander Wlodawer; Ettore Appella; Sharlyn J Mazur
Journal:  Biochemistry       Date:  2009-02-17       Impact factor: 3.162

10.  Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2.

Authors:  D P Teufel; M Bycroft; A R Fersht
Journal:  Oncogene       Date:  2009-04-13       Impact factor: 9.867

View more
  7 in total

1.  Just a Flexible Linker? The Structural and Dynamic Properties of CBP-ID4 Revealed by NMR Spectroscopy.

Authors:  Alessandro Piai; Eduardo O Calçada; Thomas Tarenzi; Alessandro Del Grande; Mihaly Varadi; Peter Tompa; Isabella C Felli; Roberta Pierattelli
Journal:  Biophys J       Date:  2016-01-19       Impact factor: 4.033

Review 2.  Role of Intrinsic Protein Disorder in the Function and Interactions of the Transcriptional Coactivators CREB-binding Protein (CBP) and p300.

Authors:  H Jane Dyson; Peter E Wright
Journal:  J Biol Chem       Date:  2016-02-05       Impact factor: 5.157

3.  Structural insights into interactions of C/EBP transcriptional activators with the Taz2 domain of p300.

Authors:  Prasenjit Bhaumik; Jamaine Davis; Joseph E Tropea; Scott Cherry; Peter F Johnson; Maria Miller
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2014-06-29

Review 4.  Transcriptional/epigenetic regulator CBP/p300 in tumorigenesis: structural and functional versatility in target recognition.

Authors:  Feng Wang; Christopher B Marshall; Mitsuhiko Ikura
Journal:  Cell Mol Life Sci       Date:  2013-01-11       Impact factor: 9.261

Review 5.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

6.  Structure of p300 bound to MEF2 on DNA reveals a mechanism of enhanceosome assembly.

Authors:  Ju He; Jun Ye; Yongfei Cai; Cecilia Riquelme; Jun O Liu; Xuedong Liu; Aidong Han; Lin Chen
Journal:  Nucleic Acids Res       Date:  2011-01-29       Impact factor: 16.971

7.  Interaction of the transactivation domain of B-Myb with the TAZ2 domain of the coactivator p300: molecular features and properties of the complex.

Authors:  Ojore Oka; Lorna C Waters; Sarah L Strong; Nuvjeevan S Dosanjh; Vaclav Veverka; Frederick W Muskett; Philip S Renshaw; Karl-Heinz Klempnauer; Mark D Carr
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.